Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Calvo

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
BMC Public Health|April 3, 2016
Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria studyAlbert Goday, Eva Calvo, Luis Alberto Vázquez, et al.
NPJ Vaccines|August 29, 2025
The 40Fp8 vaccine strain is safe and protects pregnant ewes from a virulent RVFV challengeBelén Borrego, Celia Alonso, Sandra Moreno, et al.
Virus Research|November 30, 2013
Recombinant vaccines against bluetongue virusEva Calvo-Pinilla, Javier Castillo-Olivares, Tamara Jabbar, et al.
Clinical Oral Investigations|March 2, 2019
Prediabetes and diabetes prevalence in the Workers' Oral Health StudyEduardo Montero, Miguel Carasol, Ana Fernández-Meseguer, et al.
Microorganisms|December 30, 2020
Viral Vector Vaccines against Bluetongue VirusLuis Jiménez-Cabello, Sergio Utrilla-Trigo, Eva Calvo-Pinilla, et al.
Virus Research|December 17, 2013
Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisationEva Calvo-Pinilla, Francisco de la Poza, Simon Gubbins, et al.
Antiviral Research|February 4, 2015
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challengeEva Calvo-Pinilla, Francisco de la Poza, Simon Gubbins, et al.
Gaceta Sanitaria|March 20, 2012
[Predictors of the duration of non-work-related sick leave due to anxiety disorders]Carlos Catalina-Romero, Paloma Martínez-Muñoz, Luis Quevedo-Aguado, et al.
Vaccine|February 16, 2011
Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigenValentina Franceschi, Antonio Capocefalo, Eva Calvo-Pinilla, et al.
Journal of Exposure Science & Environmental Epidemiology|April 23, 2015
Cadmium levels in a representative sample of the Spanish adult population: The BIOAMBIENT.ES projectAna López-Herranz, Francisco Cutanda, Marta Esteban, et al.
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
BMC Public Health|April 3, 2016
Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria studyAlbert Goday, Eva Calvo, Luis Alberto Vázquez, et al.
NPJ Vaccines|August 29, 2025
The 40Fp8 vaccine strain is safe and protects pregnant ewes from a virulent RVFV challengeBelén Borrego, Celia Alonso, Sandra Moreno, et al.
Virus Research|November 30, 2013
Recombinant vaccines against bluetongue virusEva Calvo-Pinilla, Javier Castillo-Olivares, Tamara Jabbar, et al.
Clinical Oral Investigations|March 2, 2019
Prediabetes and diabetes prevalence in the Workers' Oral Health StudyEduardo Montero, Miguel Carasol, Ana Fernández-Meseguer, et al.
Microorganisms|December 30, 2020
Viral Vector Vaccines against Bluetongue VirusLuis Jiménez-Cabello, Sergio Utrilla-Trigo, Eva Calvo-Pinilla, et al.
Virus Research|December 17, 2013
Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisationEva Calvo-Pinilla, Francisco de la Poza, Simon Gubbins, et al.
Antiviral Research|February 4, 2015
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challengeEva Calvo-Pinilla, Francisco de la Poza, Simon Gubbins, et al.
Gaceta Sanitaria|March 20, 2012
[Predictors of the duration of non-work-related sick leave due to anxiety disorders]Carlos Catalina-Romero, Paloma Martínez-Muñoz, Luis Quevedo-Aguado, et al.
Vaccine|February 16, 2011
Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigenValentina Franceschi, Antonio Capocefalo, Eva Calvo-Pinilla, et al.
Journal of Exposure Science & Environmental Epidemiology|April 23, 2015
Cadmium levels in a representative sample of the Spanish adult population: The BIOAMBIENT.ES projectAna López-Herranz, Francisco Cutanda, Marta Esteban, et al.
Pageof 14